Fiscal Year End | Company Status | Exempt Flag |
December 31 | Halt | N |
|
|
|
|
|
Incorporation Locations |
Inc. Date | Expiry Date | Country | Region | Description |
24/Apr/1967 | | Canada | British Columbia | |
|
|
Exchange Filing Office |
Location |
Vancouver Regional Service Office |
|
| |
Business Type(s) |
Primary/Secondary | Business Type | Details |
Primary
| Research And Development In The Life Sciences
| News Release July 17, 2014-RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function such as chronic tendinosis, damaged skin and pattern baldness. The company's RCT-01 and RCS-01 cell therapies are designed to treat chronic tendinosis and damaged or aging skin respectively, using fibroblasts isolated from the sheath of the hair follicle. Another of the company's pipeline products, RCH-01 for the treatment of pattern baldness, is manufactured from cells derived from the hair follicle dermal cup. Shiseido Company, Limited has an exclusive geographic license for RCH-01 in certain Asian countries including Japan, China and South Korea. All product candidates are based on RepliCel's innovative technology which utilizes cells isolated from a patient's own healthy hair follicles to address specific cellular deficits.
|
|
|
Securities |
Symbol | Security Name | Market | Status |
RP | Replicel Life Sciences Inc. | TSX Venture | HALT |
|
|
Name History | From | To |
RepliCel Life Sciences Inc. | 26/Jul/2013 | Present |
|
|
Company Facts Reconciliation |
Subject | Date Returned |
Spring 2015 CFR | Not Received |
|
|
|
|